Editas Medicine Inc
EDITHealthcare|Biotechnology|USA
$3.26
-0.03 (-0.76%)
Tangible Book
$0.05
About
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Stock Price
+6.5%(1Y)
Pipeline Summary
5 total trials3
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
Unknown: 1Completed: 1ENROLLING_BY_INVITATION: 1Active: 2
Active Trials (2)
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
NCT04853576Sickle Cell Disease
Phase 1Phase 2Active
Enrollment: 45 participants
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
NCT05444894Transfusion Dependent Beta Thalassemia
Phase 1Phase 2Active
Enrollment: 9 participants
BioScore
4.2/10
Cautious
Ownership
Recent Insider Trades
Parison AmySELL
2026-06-03464 shares @ $2.7
O'Neill Gilmore NeilSELL
2026-06-0315,380 shares @ $2.7
Burkly LindaSELL
2026-06-03731 shares @ $2.7
Burkly LindaSELL
2026-03-03749 shares @ $2.02
O'Neill Gilmore NeilSELL
2026-03-035,394 shares @ $2.02
Recent News
2026-06-17 18:00:20
Data last updated: Jul 13, 2026, 12:50 PM